中国生物制药拟5亿美元收购创新药企,后者曾与阿斯利康、默沙东达成授权交易

澎湃新闻
Jul 15, 2025

港股制药龙头中国生物制药将明星biotech(生物科技公司)礼新医药收入麾下。7月15日晚间,中国生物制药(01177.HK)公告,将以约5亿美元的总价收购上海礼新医药95.09%股权,加上此前参与礼新C轮融资时既已取得的4.91%股权,交易完成后,礼新医药将成为中国生物制药全资子公司。礼新医药主要研发和管理团队也将连同其备受关注的双抗、ADC等研发平台一起,加入中国生物制药。礼新医药于2019年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10